Skip to main content

Bruker Updates '09 Guidance; Expects 2 Percent Revenue Decline

NEW YORK (GenomeWeb News) – Bruker today provided updated financial guidance for fiscal year 2009, saying in a presentation at the Thomas Weisel Partners Healthcare Conference in Boston that it expects a year-over-year revenue decline of approximately 2 percent.

The firm had previously said that it expected flat to a low single-digit decline in revenues for the year.

Bruker also said that it is not likely to meet its previous goal of improving upon its 2008 earnings per share of $.45.

However, Bruker said that global stimulus programs could contribute 5 percent — roughly $50 million — or greater revenue growth its core scientific business instruments business in 2010.

Two weeks ago, the firm had revealed in a filing with the US Securities and Exchange Commission that it had taken in $10 million in orders due to stimulus programs in the US, Japan, and Europe.

In early trade on the Nasdaq, shares of Bruker were up 2 percent at $11.

Filed under

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.